Key result
CCR5-deficient mice rapidly reject cardiac allografts within 14 days compared to wild-type recipients.
Why the study?
Mechanisms of class I MHC antibody-mediated cardiac allograft injury remain unclear and require investigation in relevant murine models.
Answers are grounded in this paper and cite their sources.
Continual production of antidonor class I MHC antibody can mediate cardiac allograft rejection, and donor-reactive CD8 T cells synergize with the antibody to contribute to rejection.
Murine CCR5(-/-) recipients produce high titers of antibody to complete MHC-mismatched heart and renal allografts. To study mechanisms of class I MHC antibody-mediated allograft injury, we tested the rejection of heart allografts transgenically expressing a single class I MHC disparity in wild-type C57BL/6 (H-2(b)) and B6.CCR5(-/-) recipients. Donor-specific antibody titers in CCR5(-/-) recipients were 30-fold higher than in wild-type recipients. B6.K(d) allografts survived longer than 60 days in wild-type recipients whereas CCR5(-/-) recipients rejected all allografts within 14 days. Rejection was accompanied by infiltration of CD8 T cells, neutrophils and macrophages, and C4d deposition in the graft capillaries. B6.K(d) allografts were rejected by CD8(-/-)/CCR5(-/-), but not μMT(-/-)/CCR5(-/-), recipients indicating the need for antibody but not CD8 T cells. Grafts recovered at day 10 from CCR5(-/-) and CD8(-/-)/CCR5(-/-) recipients and from RAG-1(-/-) allograft recipients injected with anti-K(d) antibodies expressed high levels of perforin, myeloperoxidase and CCL5 mRNA. These studies indicate that the continual production of antidonor class I MHC antibody can mediate allograft rejection, that donor-reactive CD8 T cells synergize with the antibody to contribute to rejection, and that expression of three biomarkers during rejection can occur in the absence of this CD8 T cell activity.
No takes yet. Share an insight, caveat, or question.
Hattori et al. (2012) studied Cardiac allograft rejection. CCR5(-/-) knockout vs. Wild-type C57BL/6 recipients was evaluated on Allograft survival. CCR5(-/-) mice rejected single class I MHC-disparate cardiac allografts within 14 days, whereas allografts survived longer than 60 days in wild-type recipients.
Synapse has enriched 10 related papers. Consider them for comparative context: